ºÚÁÏÍø´óʼÇ

Congratulations to Prof. Holst on being awarded an NHMRC Ideas Grant to lead a groundbreaking research project aimed at Personalising neoadjuvant therapy for early-stage, high-risk triple-negative breast cancer (TNBC).

Ìý

Prof. Holst leads the Translational Cancer Metabolism Laboratory. He is Director of Engagement in the School of Biomedical Sciences at ºÚÁÏÍø´óÊÂ¼Ç Sydney and a member of the ºÚÁÏÍø´óÊÂ¼Ç Cancer Theme Strategic Advisory Committee.

This significant funding will support collaborative efforts between clinicians, scientists, and patient advocates to translate research findings into clinical applications. This initiative underscores the growing importance of personalised medicine in transforming cancer care and highlights the excellence of Australian research in this critical field.